Patient satisfaction of Depot Medroxyprogesterone Acetate (dmpa-sc) injection as contraceptive

被引:0
|
作者
Chaudhri, Rizwana [1 ]
Rizvi, Farwa [2 ]
Afzal, Muhammad [3 ]
机构
[1] Holy Family Hosp, Dept Gynecol & Obstet, Rawalpindi, Pakistan
[2] Islamabad Med & Dent Coll, Dept Community Med, Islamabad, Pakistan
[3] CPSP, RTMC, Islamabad, Pakistan
关键词
SUBCUTANEOUS INJECTION; HEALTH-CARE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine Patient Satisfaction of DMPA-SC (104 mg/0.65 mL) injected subcutaneously once every 3 months. Methods: It was a Descriptive case series with the centre in Rawalpindi (Holy Family Hospital, Gynecology and Obstetrics Unit), Pakistan. Twenty five patients were selected by purposive sampling and followed up in Rawalpindi center (Holy Family Hospital, Gynaecology and Obstetric Unit) for one year as a part of the Asian Trial These patients had successfully completed their contraception using DMPA-sc at 3 months interval. Hospital Ethical Committee Permission was obtained prior to commencement of study. Informed written consent was taken from the patients. Body weight was measured at baseline and every 3 months thereafter. Bleeding analysis was also done at 3 months interval using a 5 point scale based on patient's own records. Participant satisfaction with treatment results was evaluated using a patient satisfaction questionnaire (PSQ). It collected data regarding the respondent's experience with the study, the aspects of treatment that were liked and disliked and the likelihood of selecting that method for future contraceptive purposes. Results: Out of twenty five, 15 (60%) patients had a high inclination Six (24%) patients and 9 (36%) very highly likely to use this contraceptive method in future. Eleven (44%) women replied that the probability of recommending this contraceptive method to their friends was very highly likely. Conclusions: DMPA-SC has a very high percentage score of Patient Satisfaction for the contraceptive method as well as its likelihood of selecting it in future (JPMA 60:536; 2010).
引用
收藏
页码:536 / 540
页数:5
相关论文
共 50 条
  • [1] Women's satisfaction, use, storage and disposal of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) during a randomized trial
    Burke, Holly M.
    Chen, Mario
    Buluzi, Mercy
    Fuchs, Rachael
    Wevill, Silver
    Venkatasubramanian, Lalitha
    Dal Santo, Leila
    Ngwira, Bagrey
    CONTRACEPTION, 2018, 98 (05) : 418 - 422
  • [2] Client and provider experiences with self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Malawi
    Burke, Holly M.
    Packer, Catherine
    Buluzi, Mercy
    Healy, Elise
    Ngwira, Bagrey
    CONTRACEPTION, 2018, 98 (05) : 405 - 410
  • [3] Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results
    Okegbe, Tishina
    Affo, Jean
    Djihoun, Florence
    Zannou, Alexis
    Hounyo, Odilon
    Ahounou, Gaston
    Bangbola, Karamatou Adegnika
    Harris, Nancy
    GLOBAL HEALTH-SCIENCE AND PRACTICE, 2019, 7 (02): : 228 - 239
  • [4] Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) ?
    Kohn, Julia E.
    Berlan, Elise D.
    Tang, Jennifer H.
    Beasley, Anitra
    CONTRACEPTION, 2022, 112 : 11 - 13
  • [5] Contraceptive efficacy and safety of DMPA-SC
    Jain, J
    Jakimiuk, AJ
    Bode, FR
    Ross, D
    Kaunitz, AM
    CONTRACEPTION, 2004, 70 (04) : 269 - 275
  • [6] RETURN OF FERTILITY AFTER DEPOT MEDROXYPROGESTERONE ACETATE DMPA CONTRACEPTIVE INJECTIONS
    MCDANIEL, EB
    PRADTHAISONG, T
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1978, 9 (09): : 861 - 861
  • [7] Depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL (DMPA-SC 104) is associated with fewer hypoestrogenic symptoms in patients with endometriosis than leuprolide acetate.
    Carson, SA
    Jain, JK
    FERTILITY AND STERILITY, 2005, 84 : S191 - S192
  • [8] Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries
    Stout, Anna
    Wood, Siri
    Barigye, George
    Kabore, Alain
    Siddo, Daouda
    Ndione, Ida
    GLOBAL HEALTH-SCIENCE AND PRACTICE, 2018, 6 (01): : 55 - 72
  • [9] Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) Injectable Contraception at Facility and Community Levels: Pilot Results From 4 Districts of Uganda
    Odwe, George
    Gray, Kate
    Kyarimpa, Annet
    Obare, Francis
    Nagendi, Grace
    GLOBAL HEALTH-SCIENCE AND PRACTICE, 2018, 6 (04): : 711 - 722
  • [10] Factors Affecting Continued Use of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC): A Secondary Analysis of a 1-Year Randomized Trial in Malawi
    Burke, Holly M.
    Chen, Mario
    Buluzi, Mercy
    Fuchs, Rachael
    Wevill, Silver
    Venkatasubramanian, Lalitha
    Dal Santo, Leila
    Ngwira, Bagrey
    GLOBAL HEALTH-SCIENCE AND PRACTICE, 2019, 7 (01): : 54 - 65